Genetic polymorphisms of cytochrome P450 2C9 causing reduced phenprocoumon (S)-7-hydroxylation in vitro and in vivo

References

• AITHAL, G. P., DAY, C. P., KESTEVEN, P. J. and DALY, A. K., 1999, Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet, 353, 717–719.
   PubMed Web of Science ®Google Scholar
• AYNACIOGLU, A. S., BROCKMOLLER, J., BAUER, S., SACHSE, C., GUZELBEY, P., ONGEN, Z., NACAK, M. and ROOTS, I., 1999, Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. British Journal of Pharmacology, 48, 409–415.
   Google Scholar
• DE BOER-VAN DEN BERG, M., THIJSSEN, H. H. and VERMEER, C., 1986, The in vivo effects of acenocoumarol, phenprocoumon and warfarin on vitamin K epoxide reductase and vitamin K-dependent carboxylase in various tissues of the rat. Biochimica et Biophysica Acta, 884, 150–157.
   Google Scholar
• DE VRIES, J. X., 1990, Determination of the plasma protein binding of the coumarin anticoagulants phenprocoumon, and its metabolites, warfarin, and acenocoumarol by ultrafiltration and high-performance liquid chromatography. Journal of Chromatography, 529, 479–485.
   PubMedGoogle Scholar
• DIETERLE, W., FAIGLE, J. W., MONTIGEL, C., SULC, M. and THEOBALD, W., 1977, Biotransformation and pharmacokinetics of acenocoumarol (Sintrom) in man. European Journal of Clinical Pharmacology, 11, 367–375.
   PubMed Web of Science ®Google Scholar
• GUENGERICH, F. P., 1995, Human cytochrome P450 enzymes. In P. R. Ortiz de Montellano (ed.), Cytochrome P450 — Structure, Mechanism, and Biochemistry (New York: Plenum), pp. 473–536.
   Google Scholar
• HAINING, R. L., HUNTER, A. P., VERONESE, M. E., TRAGER, W. F. and RETTIE, A. E., 1996, Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms. Archives of Biochemistry and Biophysics, 333, 447–458.
   PubMed Web of Science ®Google Scholar
• HE, M., KORZEKWA, K. R., JONES, J. P., RETTIE, A. E. and TRAGER, W. F., 1999, Structural forms of phenprocoumon and warfarin that are metabolized at the active site of CYP2C9. Archives of Biochemistry and Biophysics, 372, 16–28.
   PubMed Web of Science ®Google Scholar
• HERMANS, J. J. and THIJSSEN, H. H., 1993, Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics. British Journal of Pharmacology, 110, 482–490.
   PubMed Web of Science ®Google Scholar
• HIRSH, J., DALEN, J. E., ANDERSON, D. R., POLLER, L., BUSSEY, H., ANSELL, J., DEYKIN, D. and BRANDT, J. T., 1998, Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest, 114, 445S–469S.
   Google Scholar
• HUMMERS-PRADIER, E., HESS, S., ADHAM, I. M., PAPKE, T., PIESKE, B. and KOCHEN, M. M., 2003, Determination of bleeding risk using genetic markers in patients taking phenprocoumon. European Journal of Clinical Pharmacology, 59, 213–219.
   Google Scholar
• KAMINSKY, L. S. and ZHANG, Z. Y., 1997, Human P450 metabolism of warfarin. Pharmacology and Therapeutics, 73, 67–74.
   PubMed Web of Science ®Google Scholar
• KAMMERER, B., KAHLICH, R., UFER, M., LAUFER, S. and GLEITER, C. H., 2004, Determination of (R)-and (S)-phenprocoumon in human plasma by enantioselective liquid chromatography/ electrospray ionisation tandem mass spectrometry. Rapid Communications in Mass Spectrometry, 18, 458–464.
   PubMedGoogle Scholar
• KESSLER, H. H., MUHLBAUER, G., STELZL, E., DAGHOFER, E., SANTNER, B. I. and MARTH, E., 2001, Fully automated nucleic acid extraction: MagNA Pure LC. Clinical Chemistry, 47, 1124–1126.
   PubMed Web of Science ®Google Scholar
• KIRCHHEINER, J., UFER, M., WALTER, E. C., KAMMERER, B., KAHLICH, R., MEISEL, C., SCHWAB, M., GLEITER, C. H., RANE, A., ROOTS, I. and BROCKMOLLER, J., 2004, Effects of CYP2C9 polymorphisms on the pharmacokinetics of R- and S-phenprocoumon in healthy volunteers. Pharmacogenetics, 14, 19–26.
   PubMedGoogle Scholar
• LEE, C. R., GOLDSTEIN, J. A. and PIEPER, J. A., 2002, Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics, 12, 251–263.
   PubMedGoogle Scholar
• LEVINE, M. N., RASKOB, G., LANDEFELD, S. and KEARON, C., 2001, Hemorrhagic complications of anticoagulant treatment. Chest, 119, 108S–121S.
   Google Scholar
• LEWIS, R. J. and TRAGER, W. F., 1970, Warfarin metabolism in man: identification of metabolites in urine. Journal of Clinical Investigation, 49, 907–913.
   PubMed Web of Science ®Google Scholar
• LOWRY, O. H., ROSEBROUGH, N. J., FARR, A. L. and RANDALL, R. J., 1951, Protein measurements with the folin phenol reagent. Journal of Biological Chemistry, 193, 265–275.
   PubMed Web of Science ®Google Scholar
• OMURA, T. and SATO, R., 1964, The carbon monoxide-binding pigment of liver microsomes — evidence of its hemoprotein nature. Journal of Biological Chemistry, 239, 2370–2378.
   PubMed Web of Science ®Google Scholar
• PETERSEN, D., BARTHELS, M., SCHUMANN, G. and BUTTNER, J., 1993, Concentrations of phenprocoumon in serum and serum water determined by high-performance liquid chromatography in patients on oral anticoagulant therapy. Haemostasis, 23, 83–90.
   PubMedGoogle Scholar
• POHL, L. R., HADDOCK, R., GARLAND, W. A. and TRAGER, W. F., 1975, Synthesis and thin-layer chromatographic ultraviolet, and mass spectral properties of the anticoagulant phenprocoumon and its monohydroxylated derivatives. Journal of Medical Chemistry, 18, 513–519.
   PubMedGoogle Scholar
• RETTIE, A. E., WIENKERS, L. C., GONZALEZ, F. J., TRAGER, W. F. and KORZEKWA, K. R., 1994, Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics, 4, 39–42.
   PubMedGoogle Scholar
• SCORDO, M. G., PENGO, V., SPINA, E., DAHL, M. L., GUSELLA, M. and PADRINI, R., 2002, Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clinical Pharmacology and Therapeutics, 72, 702–710.
   PubMed Web of Science ®Google Scholar
• STUBBINS, M. J., HARRIES, L. W., SMITH, G., TARBIT, M. H. and WOLF, C. R., 1996, Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics, 6, 429–439.
   PubMedGoogle Scholar
• SULLIVAN-KLOSE, T. H., GHANAYEM, B. I., BELL, D. A., ZHANG, Z. Y., KAMINSKY, L. S., SHENFIELD, G. M., MINERS, J. O., BIRKETT, D. J. and GOLDSTEIN, J. A., 1996, The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics, 6, 341–349.
   Google Scholar
• TAKAHASHI, H. and ECHIZEN, H., 2001, Pharmacogenetics of warfarin elimination and its clinical implications. Clinical Pharmacokinetics, 40, 587–603.
   PubMed Web of Science ®Google Scholar
• TAKAHASHI, H., KASHIMA, T., NOMOTO, S., IWADE, K., TAINAKA, H., SHIMIZU, T., Nomizo, Y., MURAMOTO, N., KIMURA, S. and ECHIZEN, H., 1998, Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes. Pharmacogenetics, 8, 365–373.
   PubMedGoogle Scholar
• TAUBE, J., HALSALL, D. and BAGLIN, T., 2000, Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood, 96, 1816–1819.
   PubMed Web of Science ®Google Scholar
• THIJSSEN, H. H., DRITTIJ, M. J., VERVOORT, L. M. and de VRIES-HANJE, J. C., 2001, Altered pharmacokinetics of R- and S-acenocoumarol in a subject heterozygous for CYP2C9*3. Clinical Pharmacology and Therapeutics, 70, 292–298.
   Google Scholar
• THIJSSEN, H. H., FLINOIS, J. P. and BEAUNE, P. H., 2000a, Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes. Drug Metabolism and Disposition, 28, 1284–1290.
   PubMed Web of Science ®Google Scholar
• THIJSSEN, H. H., VERKOOIJEN, I. W. and FRANK, H. L., 2000b, The possession of the CYP2C9*3 allele is associated with low dose requirement of acenocoumarol. Pharmacogenetics, 10, 757–760.
   PubMedGoogle Scholar
• TOON, S., HEIMARK, L. D., TRAGER, W. F. and O'REILLY, R. A., 1985, Metabolic fate of phenprocoumon in humans. Journal of Pharmacological Sciences, 74, 1037–1040.
   Google Scholar
• TOWBIN, H., STAEHELIN, T. and GORDON, J., 1979, Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proceedings of the National Academy of Sciences, USA, 76, 4350–4354.
   PubMed Web of Science ®Google Scholar
• UFER, M., KAMMERER, B., KIRCHHEINER, J., RANE, A. and SVENSSON, J. O., 2004a, Determination of phenprocoumon, warfarin and their monohydroxylated metabolites in human plasma and urine by high-performance liquid chromatography-mass spectrometry after solid-phase extraction. Journal of Chromatography B, 809, 217–226.
   PubMed Web of Science ®Google Scholar
• UFER, M., SVENSSON, J. O., KRAUSZ, K. W., GELBOIN, H. V., RANE, A. and TYBRIN G., 2004b, Identification of cytochromes P450 2C9 and 3A4 as the major catalysts of phenprocoumon hydroxylation in vitro. European Journal of Clinical Pharmacology, 60, 173–182.
   PubMed Web of Science ®Google Scholar
• VISSER, L. E., VAN VLIET, M., VAN SCHAIK, R. H., KASBERGEN, A. A., DE SMET, P. A., VULTO, A. G., HOFMAN, A., VAN DUIJN, C. M. and STRICKER, B. H., 2004, The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 and CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Pharmacogenetics, 14, 27–33.
   PubMedGoogle Scholar
• VON BAHR, C., GROTH, C. G., JANSSON, H., LUNDGREN, G., LIND, M. and GLAUMANN, H., 1980, Drug metabolism in human liver in vitro: establishment of a human liver bank. Clinical Pharmacology and Therapeutics, 27, 711–725.
   PubMedGoogle Scholar
• WIENKERS, L. C., WURDEN, C. J., STORCH, E., KUNZE, K. L., RETTIE, A. E. and TRAGER, W. F., 1996, Formation of (R)-8-hydroxywarfarin in human liver microsomes. A new metabolic marker for the (S)-mephenytoin hydroxylase, P4502C19. Drug Metabolism and Disposition, 24, 610–614.
   PubMed Web of Science ®Google Scholar
• YAMAZAKI, H., INouE, K., CHIBA, K., OZAWA, N., KAWAI, T., SUZUKI, Y., GOLDSTEIN, J. A., GUENGERICH, F. P. and SHIMADA, T., 1998a, Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes. Biochemical Pharmacology, 56, 243–251.
   PubMed Web of Science ®Google Scholar
• YAMAZAKI, H., INouE, K. and SHIMADA, T., 1998b, Roles of two allelic variants (Arg144Cys and Ile359Leu) of cytochrome P4502C9 in the oxidation of tolbutamide and warfarin by human liver microsomes. Xenobiotica, 28, 103–115.
   PubMed Web of Science ®Google Scholar
• YASAR, C., ELIASSON, E., DAHL, M. L., JOHANSSON, I., INGELMAN-SUNDBERG, M. and SJOQVIST, F., 1999, Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. Biochemical Biophysical Research Communications, 254, 628–631.
   Google Scholar
• YASAR, C., TYBRING, G., HIDESTRAND, M., OSCARSON, M., INGELMAN-SUNDBERG, M., DAHL, M. L. and ELIASSON, E., 2001, Role of CYP2C9 polymorphism in losartan oxidation. Drug Metabolism and Disposition, 29, 1051–1056.
   Google Scholar
• YASUKOCHI, Y. and MASTERS, B. S., 1976, Some properties of a detergent-solubilized NADPH-cytochrome c(cytochrome P-450) reductase purified by biospecific affinity chromatography. Journal of Biological Chemistry, 251, 5337–5344.
   PubMed Web of Science ®Google Scholar
• ZHANG, Z. Y., KERR, J., WEXLER, R. S., Li, H. Y., ROBINSON, A. J., HARLOW, P. P. and KAMINSKY, L. S., 1997, Warfarin analog inhibition of human CYP2C9-catalyzed S-warfarin 7-hydroxylation. Thrombosis Research, 88, 389–398.
   PubMedGoogle Scholar